Mao Luo

Mao Luo

Auto-generated profile, based on publicly available information

Mao Luo

Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University , No. 1 Youyi Road, Yuzhong District, Chongqing 400016

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Skin Research and Technology
Verified
Journal Article
Open access
MLMao Luo
Mao Luo
BWBin Wei
Bin Wei
Background: Chronic inflammation has been shown to promote cancer progression. Rosacea is indeed a long‐term inflammatory skin condition and had been reported to link with increased risk for several types of malignancies, but evidence for causality is lacking. Objectives: To systematically estimate the causal relationship between rosacea and several types of cancer, including cutaneous malignant melanoma (CMM), cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), actinic keratosis (AK), thyroid cancer, breast cancer, glioma and hepatic cancer, as well as explore the potential underlying pathogenesis. Methods: We conducted a bidirectional two‐sample Mendelian randomization study to probe the potential causal relationships between rosacea and several types of cancer. Instrumental variables were established using genome‐wide significant single nucleotide polymorphisms associated with rosacea and cancers. The assessment of causality was carried out through multiple methods, and the robustness of the results was evaluated via sensitivity analyses. Results: There was no significant indication of causal effects of rosacea on CMM ( p ivw = 0.71), cSCC ( p ivw = 0.45), BCC ( p ivw  = 0.90), AK ( p ivw = 0.73), thyroid cancer ( p ivw = 0.59), glioma ( p ivw = 0.15), and hepatic cancer ( p ivw  = 0.07), but the genetic risk of rosacea was associated with an increased susceptibility to human epidermal growth factor receptor (HER)‐negative malignant neoplasm of breast (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02–1.18; p ivw = 0.01). TANK (TRAF family member associated nuclear factor kappa B (NFKB) activator) was identified as a common protective gene for both rosacea (OR, 0.90; 95% CI, 0.82–0.99; p ivw = 0.048) and HER‐negative malignant neoplasm of the breast (OR, 0.86; 95% CI, 0.75–0.98; p ivw = 0.032), which was primarily enriched in the negative regulation of NF‐κB signal transduction and may contribute to the genetic links between rosacea and this subtype of breast cancer. Conclusions: Our findings provide suggestive evidence for causal links between rosacea and HER‐negative malignant neoplasm of the breast risk.

29 October 2024 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
MLMao Luo
Mao Luo
ZJZiqi Jiang
Ziqi Jiang
PWPing Wang
Ping Wang
YCYangmei Chen
Yangmei Chen
ACAijun Chen
Aijun Chen
BWBin Wei
Bin Wei
Pemphigus vulgaris (PV) is an autoimmune skin disorder characterized by the loss of cell cohesion, with the histone deacetylase 1 (HDAC1) and lysine demethylase 1A (KDM1A) playing critical roles in its pathogenesis. This study aimed to elucidate the molecular mechanisms behind PV, focusing on the function of HDAC1 and KDM1A in disease onset and progression. Based on in vitro and in vivo PV models, we observed a significant increase in HDAC1 mRNA and protein levels in skin tissues of PV patients. Inhibition of HDAC1 ameliorated cell damage and reduced the loss of cell cohesion in human epidermal keratinocytes (HEKs) induced by PV-IgG. Our findings suggest that HDAC1 regulates KDM1A expression through deacetylation, with a notable deficiency in KDM1A expression in PV. Overexpression of KDM1A mitigated cell damage and cohesion loss. The extracellular signal-regulated kinase (ERK) pathway serves as a downstream executor of the HDAC1/KDM1A axis. Inhibiting HDAC1 and increasing KDM1A expression suppressed ERK phosphorylation, reducing PV-related apoptosis. These insights provide a new perspective on treating PV, highlighting the therapeutic potential of targeting HDAC1 expression. The regulatory mechanism of the HDAC1/KDM1A/ERK axis offers crucial clues for understanding PV pathogenesis and developing novel treatments.